EDTA enhances antimicrobial activity of PR-39 and Protegrin-1 antimicrobial peptides against carbapenem-resistant Pseudomonas aeruginosa in serum.
Carbapenem-resistant Pseudomonas aeruginosa isn’t just a mouthful—it's one of the toughest bacteria out there. Researchers just found a way to boost the power of PR-39 and Protegrin-1 antimicrobial peptides against this stubborn bug, even in the tricky conditions of serum.
Folia Microbiol (Praha)
by Vacek L, Pavelka A, Lipový B et al.
“EDTA enhances antimicrobial activity of PR-39 and Protegrin-1 antimicrobial peptides against carbapenem-resistant Pseudomonas aeruginosa in serum. Vacek L(1), Pavelka A(2)(3), Lipový B(4)(5), Brtníková J(5), Straková P(2), Jeklová E(2), Šefranko M(1), Kleknerová DP(1), Volný F(1), Janda L(2), Vojtová L(5), Růžička F(6). Author information: (1)Department of Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Pekařská 53, Brno, 602 00, Czech Republic. (2)Infectious Diseases and Preventive Medicine, Veterinary Research Institute, Hudcova 296/70, Brno, 621 00, Czech Republic. (3)National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic. (4)Department of Burns Medicine, Third Faculty of Medicine, Charles University, University Hospital Královské Vinohrady, Šrobárova 50, Prague, 100 34, Czech Republic. (5)Advanced Biomaterials Group, Central European Institute of Technology, Brno University of Technology, Purkyňova 656/123, Brno, 612 00, Czech Republic. (6)Department of Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Pekařská 53, Brno, 602 00, Czech Republic. filip.ruzicka@fnusa.cz. Carbapenem-resistant Pseudomonas aeruginosa represents a frequent and clinically challenging pathogen responsible for both acute and chronic infections. Antimicrobial peptides are emerging as a promising class of novel therapeutic agents due to their broad-spectrum activity, rapid bactericidal activity, and low potential to induce antimicrobial resistance. The antimicrobial efficacy of these peptides can be further enhanced by EDTA. However, their activity is often reduced in the presence of serum, which contains multiple inhibitory components. In this study, EDTA fully restored the antimicrobial activity of PR-39 and Protegrin-1 in serum. Moreover, incorporation of chitosan increased the antimicrobial efficacy of the PR-39/Protegrin-1/EDTA formulation. These findings demonstrate that PR-39, Protegrin-1, EDTA, and chitosan can act synergistically, supporting the feasibility of integrating these components into a unified therapeutic platform. © 2026. The Author(s). Conflict of interest statement: Declarations. Competing interests: The authors declare no competing interests.”
Serum usually blunts the effect of antimicrobial peptides. That’s been a sticking point for researchers hunting new ways to tackle resistant infections. This study flipped the script. The team added EDTA, a well-known chelator, to the mix. Result: EDTA fully restored the antimicrobial punch of both PR-39 and Protegrin-1 in serum. That means these peptides didn’t just survive serum—they thrived.
But the team didn’t stop there. Chitosan, another biocompatible compound, got added to the PR-39/Protegrin-1/EDTA combo. The result? Even more antimicrobial activity. The data shows a clear synergy between peptides, EDTA, and chitosan.
Key takeaway:
PR-39 and Protegrin-1, with a little help from EDTA, can fight carbapenem-resistant P. aeruginosa in serum conditions.
Chitosan pushes the effect even further.
This approach could point to new platforms for antimicrobial research compounds.
For researchers, this is a clear signal: don’t write off antimicrobial peptides just because serum complicates things. With the right combination strategy, their activity can be dialed back up. Full details and more peptide breakthroughs are always just a click away in our peptide research index.
The synergy between PR-39, Protegrin-1, EDTA, and chitosan is worth exploring in your next project. This could be the scaffold for the next generation of antimicrobial research.
Related Reading
Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database.
News · J Biomol Struct DynmePTL: miRNA-encoded peptides identification using multi-source feature transformation and ensemble learning.
News · J Med ChemDouble-Stapled Peptide Scan Yields Potent Fusion Inhibitors of Respiratory Syncytial Virus.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.